{"analyses":[{"ciLowerLimit":"0.627","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.022","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0748","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.80","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.1","upperLimit":"22.3","value":"19.5"},{"groupId":"OG001","lowerLimit":"13.6","upperLimit":"22.8","value":"16.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"OG000","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"OG001","title":"Non-gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days","title":"Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation","type":"SECONDARY","unitOfMeasure":"Months"}